ClinicalTrials.gg
CompletedNCT02393859Updated Jun 26, 2026Results posted

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 3 interventional study of Blinatumomab and Dexamethasone in Leukemia, Acute Lymphoblastic, sponsored by Amgen. Completed at 103 sites in 24 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
24th of 61
111 · median 67
Started
2015
with 1 other
Phase 3
11 of 61
4 open now
Registered
10th of 61
by date
Lead sponsor
9 of 61
Amgen

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 24th largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 10th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse. In general, pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy. Standard of care chemotherapy is associated with considerable toxicity. There is a lack of novel treatment options for subjects who relapse or are refractory to treatment. Therefore, innovative therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. This study will evaluate the event-free survival (EFS) after treatment with blinatumomab when compared to standard of care (SOC) chemotherapy. The effect of blinatumomab on overall survival and reduction of minimal residual disease compared to SOC chemotherapy will also be investigated.

Read the detailed description

Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients should undergo alloHSCT depending on their bone marrow status. The patients will be followed up until the last subject on study is 36 months following alloHSCT or has died, whichever is first.

03

Conditions studied

  • Leukemia, Acute Lymphoblastic

Keywords

  • ALL
  • High-risk first relapse B-precursor ALL
  • Precursor Cell Lymphoblastic Leukemia
  • Neoplasms
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Antibodies, Bispecific
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor acute lymphoblastic leukemia (ALL; as defined by International Berlin-Frankfurt-Muenster study group/International study for treatment of childhood ALL [I-BFM SG/IntReALL] criteria)
  • Subjects with bone marrow blast percentage \< 5% (M1) or bone marrow blast percentage \< 25% and ≥5% (M2) marrow at the time of randomization,
  • Age > 28 days and \< 18 years at the time of /assent
  • Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated
  • Availability of the following material from relapse diagnosis for central analysis of minimal residual disease (MRD) by polymerase chain reaction (PCR): clone-specific primers and reference deoxyribonucleic acid (DNA), as well as primer sequences and analyzed sequences of clonal rearrangements (cases with isolated extramedullary relapse or cases with technical and/or logistic hurdles to obtain and process bone marrow material are exempt from providing this material. In these cases, central MRD analysis only by Flow is permitted).

Exclusion criteria

Exclusion Criteria:

  • central nervous system (CNS) pathology requiring treatment (eg, unstable epilepsy). Evidence of current CNS (CNS 2, CNS 3) involvement by ALL. Subjects with CNS relapse at the time of relapse are eligible if CNS is successfully treated prior to enrollment
  • Peripheral neutrophils \< 500/μL prior to start of treatment
  • Peripheral \< 50,000/μL prior to start of treatment
  • Currently receiving treatment in another device or drug study or less than 4 weeks since ending treatment on another investigational device or drug study(s), procedures required by IntReALL high-risk (HR) guidelines are allowed
  • Chemotherapy related toxicities that have not resolved to ≤ grade 2 (except for parameters defined in Exclusion Criteria 202, 203, 204, and 217)
  • Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol
  • Abnormal renal or hepatic function prior to start of treatment (day 1) as defined below
  • Abnormal serum creatinine based on age/gender
  • Total > 3.0 mg/dL prior to start of treatment (unless related to Gilbert's or Meulengracht disease)
  • Documented infection with (HIV)
  • Known to immunoglobulins or any of the products or components to be administered during dosing (excluding asparaginase)
  • Post-menarchal female subject who is pregnant or breastfeeding, or is planning to become pregnant or breastfeed while receiving protocol-specified therapy and for at least 12 months after the last dose of chemotherapy
  • Post-menarchal female subject who is not willing to practice true sexual abstinence or use a highly effective form of while receiving protocol-specified therapy and for at least 12 months after the last dose of chemotherapy
  • Sexually mature male subject who is not willing to practice true sexual abstinence or use a condom with spermicide while receiving protocol-specified therapy and for at least 6 months after last dose of chemotherapy. In countries where spermicide is not available, a condom without spermicide is acceptable
  • Sexually mature male subject who is not willing to abstain from sperm donation while receiving protocol-specified therapy and for at least 6 months after last dose of chemotherapy
  • Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
  • Placed into an institution due to juridical or regulatory ruling.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    High Risk Consolidation 3 (HC3) Chemotherapy

    One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\^2/day intravenous \[IV\] on Days 1-6), vincrisitne (1.5 mg/m\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\^2 IV for 1 hour on Days 2-4), and pegylated \[PEG\]-asparaginase (1000 U/m\^2 IV for 2 hours or intramuscularly \[IM\] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\^2 IV or IM every 48 hours for a total of 6 doses).

    Drug: Dexamethasone · Drug: Vincrisitne · Drug: Daunorubicin · Drug: Methotrexate · Drug: Ifosfamide · Drug: PEG-asparaginase · Drug: Erwinia-asparaginase

  • Experimental
    Blinatumomab

    15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks

    Drug: Blinatumomab

Interventions

  • 15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks

    Also known as: Blincyto, AMG103

  • 10 mg/m\^2/day intravenous (IV) on Days 1-6

  • DrugVincrisitne

    1.5 mg/m\^2/day IV on Days 1 and 6

  • 30 mg/m\^2 IV over 24 hours on Day 5

  • 1 g/m\^2 IV over 36 hours on Day 1

  • 800 mg/m\^2 IV for 1 hour on Days 2-4

  • 1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6

  • In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses

06

What researchers measure

Primary outcomes

  1. Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)

    EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with ≥ 5% and \< 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.

    Time frame: As of the primary analysis data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months.

  2. Kaplan Meier Estimate: EFS (Final Analysis)

    EFS is calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with IP or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.

    Time frame: At final analysis, overall median follow-up time for EFS was 51.9 months.

Secondary outcomes

  1. Kaplan Meier Estimate: Overall Survival (OS)

    OS was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive. Months were calculated as days from randomization date to event/censor date, divided by 30.5.

    Time frame: At final analysis, overall median follow-up time for OS was 55.2 months.

  2. Percentage of Participants With an MRD Response Within 29 Days of Treatment Initiation

    At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. MRD response was defined as MRD level \< 10\^-4, by polymerase chain reaction (PCR) or flow cytometry, at the end of treatment (Cycle 1 Day 29) with study drug. Participants who were part of the MRD Evaluable Set and were missing the end of treatment (Cycle 1 Day 29) assessment for a respective MRD assessment method were considered not to have achieved a response.

    Time frame: Up to End of Treatment (Cycle 1, Day 29)

  3. Cumulative Incidence of Relapse (CIR)

    CIR estimate, presented as median months to relapse, calculated from date of achievement of first CR, using the cumulative incidence method (Fine JP, Gray RJ:1999). Deaths prior to relapse not considered related to an otherwise undocumented relapse were treated as a competing risk. Participants still alive without a date of relapse were censored at the time of last follow-up. Relapse=presence of ≥1 of the following: * isolated bone marrow relapse (M3 marrow \[representative bone marrow aspirate or biopsy with ≥25% blasts\] in the absence of extramedullary involvement) * combined bone marrow relapse (M2 \[representative bone marrow aspirate or biopsy with ≥5% and \<25% blasts\] or M3 marrow and ≥1 extramedullary manifestation of acute lymphoblastic leukemia) * central nervous system extramedullary relapse * testicular extramedullary relapse * extramedullary relapse at other sites Months were calculated as days from randomization to event/censor date, divided by 30.5.

    Time frame: At final analysis, the overall maximum follow-up time was 82.0 months.

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)

    Adverse event (AE): any untoward medical occurrence. Serious AE: an AE meeting at least 1 of the following serious criteria: fatal; life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Severity was graded according to the Common Terminology Criteria for AEs (CTCAE) version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Investigational product (IP) in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine, and in the blinatumomab arm refers to blinatumomab. Treatment-related refers to the assessment of a relationship between IP and the event.

    Time frame: From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.

  5. Number of Participants With TEAEs of Interest

    TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.

    Time frame: From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.

  6. Number of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values

    Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Increases (↑) or decreases (↓) in laboratory value grades (Gr) from baseline (BL) to worst postbaseline (→ PB) grade are presented. NA=not available.

    Time frame: Up to Day 29 (± 2 days).

  7. Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

    The analysis of 100-day mortality after alloHSCT was assessed for participants who received an alloHSCT while in remission and did not receive any additional anti-leukemic treatment. 100-day mortality after alloHSCT was calculated relative to the date of alloHSCT. The 100-day mortality rate after alloHSCT was defined as the percentage of participants having died up to 100 days after alloHSCT, estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive were censored at the date they were last known to be alive.

    Time frame: From the date of alloHSCT until death/censor date; median follow up time was 1742.0 days for blinatumomab and 1619.0 days for HC3.

  8. Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)

    Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.

    Time frame: Day 1 to Day 29.

  9. Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)

    Time frame: Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15

  10. Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)

    Time frame: Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15

07

Results

Posted Jul 13, 2020

Participant flow

This study was conducted at 48 centers across 13 countries (Europe, Australia, Israel). The first participant was enrolled on 10 November 2015. The last participant enrolled on 30 August 2019. The primary completion date was 17 July 2019 and the study completion date was 21 November 2022.

Participant flow — Overall Study
MilestoneHC3 ChemotherapyBlinatumomab
Started5754
Participants treated5254
Participants in the primary analysis population5454
Participants in the final analysis population5754
Completed1633
Not completed4121
Withdrew: Decision by sponsor24
Withdrew: Withdrawal by subject116
Withdrew: Death2710
Withdrew: Lost to follow-up11

Outcome measures

PrimaryKaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)

EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with ≥ 5% and \< 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.

Time frame:
As of the primary analysis data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months.
Reported as:
Median · months
Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)
monthsHC3 ChemotherapyBlinatumomab
Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)7.4 (4.5 to 12.7)NA (12.0 to NA)
Statistical analysis
  • HC3 Chemotherapy vs Blinatumomab · Stratified log-rank test · p = < 0.001 (Stratification factors were: age (1 to 9 years vs other \[\< 1 year and \> 9 years\]), and marrow/MRD status (M1 with MRD level \< 10\^-3 vs M1 with MRD level ≥ 10\^-3 vs M2).) · Normal score: -11.54A normal score \< 0 indicates fewer than expected events for blinatumomab relative to HC3 and therefore a longer event-free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Unstratified log-rank test · p = 0.001 · Normal score: -11.16A normal score \< 0 indicates fewer than expected events for blinatumomab relative to HC3 and therefore a longer event-free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Stratified hazard ratio (hr): 0.36 · 95% CI 0.19 to 0.66Cox proportional hazard model. Stratification factors were: age and marrow/MRD status. (HR \< 1.0 indicates a lower average event rate and a longer EFS for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Unstratified hr: 0.39 · 95% CI 0.22 to 0.70Cox proportional hazard model. (HR \< 1.0 indicates a lower average event rate and a longer EFS for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Stratified hr w/time-dependent covariate: 0.36 · 95% CI 0.20 to 0.64Cox proportional hazard model including time from randomization to allogeneic hematopoietic stem cell transplant. Stratification factors: age and marrow/MRD status. (HR \<1.0=lower average event rate and longer EFS for blinatumomab relative to HC3.)
PrimaryKaplan Meier Estimate: EFS (Final Analysis)

EFS is calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with IP or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.

Time frame:
At final analysis, overall median follow-up time for EFS was 51.9 months.
Reported as:
Median · months
Kaplan Meier Estimate: EFS (Final Analysis)
monthsHC3 ChemotherapyBlinatumomab
Kaplan Meier Estimate: EFS (Final Analysis)7.8 (5.8 to 13.4)NA (24.8 to NA)
Statistical analysis
  • HC3 Chemotherapy vs Blinatumomab · Stratified log-rank test · p = < 0.001 (Stratification factors were: age (1 to 9 years vs other \[\< 1 year and \> 9 years\]), and marrow/MRD status (M1 with MRD level \< 10\^-3 vs M1 with MRD level ≥ 10\^-3 vs M2).) · Normal score: -13.90A normal score \< 0 indicates fewer than expected events for blinatumomab relative to HC3 and therefore a longer event-free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Unstratified log-rank test · p = < 0.001 · Normal score: -13.61A normal score \< 0 indicates fewer than expected events for Blinatumomab relative to HC3 and therefore a longer event free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Stratified hr: 0.35 · 95% CI 0.20 to 0.61Cox proportional hazard model. Stratification factors were: age and marrow/MRD status. (HR \< 1.0 indicates a lower average event rate and a longer EFS for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Unstratified hr: 0.38 · 95% CI 0.22 to 0.65Cox proportional hazard model. (HR \< 1.0 indicates a lower average event rate and a longer EFS for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Stratified hr w/time-dependent covariate: 0.34 · 95% CI 0.20 to 0.59Cox proportional hazard model including time from randomization to allogeneic hematopoietic stem cell transplant. Stratification factors: age and marrow/MRD status. (HR \<1.0=lower average event rate and longer EFS for blinatumomab relative to HC3.)
SecondaryKaplan Meier Estimate: Overall Survival (OS)

OS was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive. Months were calculated as days from randomization date to event/censor date, divided by 30.5.

Time frame:
At final analysis, overall median follow-up time for OS was 55.2 months.
Reported as:
Median · months
Kaplan Meier Estimate: Overall Survival (OS)
monthsHC3 ChemotherapyBlinatumomab
Kaplan Meier Estimate: Overall Survival (OS)25.6 (17.5 to NA)NA (NA to NA)
Statistical analysis
  • HC3 Chemotherapy vs Blinatumomab · Stratified log-rank test · p = 0.001 (Stratification factors were: age (1 to 9 years vs other \[\< 1 year and \> 9 years\]), and marrow/MRD status (M1 with MRD level \< 10\^-3 vs M1 with MRD level ≥ 10\^-3 vs M2).) · Normal score: -10.14A normal score \< 0 indicates fewer than expected events for blinatumomab relative to HC3 and therefore a longer event-free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Unstratified log-rank test · p = < 0.001 · Normal score: -10.32A normal score \< 0 indicates fewer than expected events for blinatumomab relative to HC3 and therefore a longer event-free survival time.
  • HC3 Chemotherapy vs Blinatumomab · Stratified hr: 0.33 · 95% CI 0.16 to 0.66Cox proportional hazard model. Stratification factors were: age and marrow/MRD status. (HR \< 1.0 indicates a lower average event rate and a longer survival for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Unstratified hr: 0.32 · 95% CI 0.16 to 0.65Cox proportional hazard model. (HR \< 1.0 indicates a lower average event rate and a longer survival for blinatumomab relative to HC3.)
SecondaryPercentage of Participants With an MRD Response Within 29 Days of Treatment Initiation

At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. MRD response was defined as MRD level \< 10\^-4, by polymerase chain reaction (PCR) or flow cytometry, at the end of treatment (Cycle 1 Day 29) with study drug. Participants who were part of the MRD Evaluable Set and were missing the end of treatment (Cycle 1 Day 29) assessment for a respective MRD assessment method were considered not to have achieved a response.

Time frame:
Up to End of Treatment (Cycle 1, Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants With an MRD Response Within 29 Days of Treatment Initiation
percentage of participantsHC3 ChemotherapyBlinatumomab
MRD Response by PCR53.1 (38.3 to 67.5)93.9 (83.1 to 98.7)
MRD Response by Flow Cytometry60.0 (45.9 to 73.0)92.6 (82.1 to 97.9)
Statistical analysis
  • HC3 Chemotherapy vs Blinatumomab · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusting for the stratification factors: age (1 to 9 years vs other \[\< 1 year and \> 9 years\]), and marrow/MRD status (M1 with MRD level \< 10\^-3 vs M1 with MRD level ≥ 10\^-3 vs M2).)
  • HC3 Chemotherapy vs Blinatumomab · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusting for the stratification factors: age (1 to 9 years vs other \[\< 1 year and \> 9 years\]), and marrow/MRD status (M1 with MRD level \< 10-3 vs M1 with MRD level ≥ 10-3 vs M2).)
SecondaryCumulative Incidence of Relapse (CIR)

CIR estimate, presented as median months to relapse, calculated from date of achievement of first CR, using the cumulative incidence method (Fine JP, Gray RJ:1999). Deaths prior to relapse not considered related to an otherwise undocumented relapse were treated as a competing risk. Participants still alive without a date of relapse were censored at the time of last follow-up. Relapse=presence of ≥1 of the following: * isolated bone marrow relapse (M3 marrow \[representative bone marrow aspirate or biopsy with ≥25% blasts\] in the absence of extramedullary involvement) * combined bone marrow relapse (M2 \[representative bone marrow aspirate or biopsy with ≥5% and \<25% blasts\] or M3 marrow and ≥1 extramedullary manifestation of acute lymphoblastic leukemia) * central nervous system extramedullary relapse * testicular extramedullary relapse * extramedullary relapse at other sites Months were calculated as days from randomization to event/censor date, divided by 30.5.

Time frame:
At final analysis, the overall maximum follow-up time was 82.0 months.
Reported as:
Median · months
Cumulative Incidence of Relapse (CIR)
monthsHC3 ChemotherapyBlinatumomab
Cumulative Incidence of Relapse (CIR)7.9 (5.8 to 18.6)NA (NA to NA)
Statistical analysis
  • HC3 Chemotherapy vs Blinatumomab · Hazard ratio (hr): 0.29 · 95% CI 0.16 to 0.52The subdistribution HR estimates are obtained from the subdistribution Cox model. (HR \< 1.0 indicates a lower average event rate and a longer relapse-free time for blinatumomab relative to HC3.)
  • HC3 Chemotherapy vs Blinatumomab · Stratified hazard ratio (hr): 0.27 · 95% CI 0.15 to 0.48The subdistribution HR estimates are obtained from the subdistribution Cox model. (HR \< 1.0 indicates a lower average event rate and a longer relapse-free time for blinatumomab relative to HC3.) Stratification factors are age and marrow/MRD status.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)

Adverse event (AE): any untoward medical occurrence. Serious AE: an AE meeting at least 1 of the following serious criteria: fatal; life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Severity was graded according to the Common Terminology Criteria for AEs (CTCAE) version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Investigational product (IP) in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine, and in the blinatumomab arm refers to blinatumomab. Treatment-related refers to the assessment of a relationship between IP and the event.

Time frame:
From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)
participantsHC3 ChemotherapyBlinatumomab
TEAEs5054
TEAEs Grade ≥ 34333
Serious TEAEs2415
Fatal TEAEs00
TEAEs Leading to Discontinuation of IP02
TEAEs Leading to Interruption of IP26
TRAEs4145
TRAEs Grade ≥ 3339
Serious TRAEs159
Fatal TRAEs00
TRAEs Leading to Discontinuation of IP02
TRAEs Leading to Interruption of IP25
SecondaryNumber of Participants With TEAEs of Interest

TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.

Time frame:
From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Reported as:
Number · participants
Number of Participants With TEAEs of Interest
participantsHC3 ChemotherapyBlinatumomab
CLS Events10
CLS Events Grade ≥ 310
Serious CLS Events10
Fatal CLS Events00
CLS Events Leading to Discontinuation of IP00
CLS Events Leading to Interruption of IP00
CRS Events12
CRS Events Grade ≥ 300
Serious CRS Events00
Fatal CRS Events00
CRS Events Leading to Discontinuation of IP00
CRS Events Leading to Interruption of IP00
DI Events69
DI Events Grade ≥ 311
Serious DI Events01
Fatal DI Events00
DI Events Leading to Discontinuation of IP00
DI Events Leading to Interruption of IP00
ELE Events157
ELE Events Grade ≥ 393
Serious ELE Events10
Fatal ELE Events00
ELE Events Leading to Discontinuation of IP00
ELE Events Leading to Interruption of IP00
ETE Events04
ETE Events Grade ≥ 302
Serious ETE Events00
Fatal ETE Events00
ETE Events Leading to Discontinuation of IP00
ETE Events Leading to Interruption of IP00
INF Events1825
INF Events Grade ≥ 3611
Serious INF Events64
Fatal INF Events00
IFN Events Leading to Discontinuation of IP00
IFN Events Leading to Interruption of IP00
IRWCD Events437
IRWCD Events Grade ≥ 302
Serious IRWCD Events01
Fatal IRWCD Events00
IRWCD Events Leading to Discontinuation of IP00
IRWCD Events Leading to Interruption of IP00
ME Events01
ME Events Grade ≥ 300
Serious ME Events01
Fatal ME Events00
ME Events Leading to Discontinuation of IP00
ME Events Leading to Interruption of IP01
NE Events1526
NE Events Grade ≥ 313
Serious NE Events15
Fatal NE Events00
NE Events Leading to Discontinuation of IP02
NE Events Leading to Interruption of IP13
NFN Events2812
NFN Events Grade ≥ 32711
Serious NFN Events120
Fatal NFN Events00
NFN Events Leading to Discontinuation of IP00
NFN Events Leading to Interruption of IP00
PNC Events10
PNC Events Grade ≥ 310
Serious PNC Events10
Fatal PNC Events00
PNC Events Leading to Discontinuation of IP00
PNC Events Leading to Interruption of IP00
Tumour Lysis Syndrome Events00
Leukoencephalopathy Events00
Immunogenicity Events00
SecondaryNumber of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values

Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Increases (↑) or decreases (↓) in laboratory value grades (Gr) from baseline (BL) to worst postbaseline (→ PB) grade are presented. NA=not available.

Time frame:
Up to Day 29 (± 2 days).
Reported as:
Number · participants
Number of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values
participantsHC3 ChemotherapyBlinatumomab
Potassium ↑ BL Gr 0 → PB Gr 301
Potassium ↓ BL Gr 0 → PB Gr 345
Potassium ↓ BL Gr 0 → PB Gr 411
Albumin ↓ BL Gr 0 → PB Gr 301
Calcium ↓ BL Gr 0 → PB Gr 411
Alanine Aminotransferase ↑ BL Gr 0 → PB Gr 310
Alanine Aminotransferase ↑ BL Gr 1 → PB Gr 395
Aspartate Aminotransferase ↑ BL Gr NA → PB Gr 310
Aspartate Aminotransferase ↑ BL Gr 0 → PB Gr 320
Aspartate Aminotransferase ↑ BL Gr 1 → PB Gr 351
Aspartate Aminotransferase ↑ BL Gr 1 → PB Gr 410
Gamma-Glutamyl Transferase ↑ BL Gr NA → PB Gr 301
Gamma-Glutamyl Transferase ↑ BL Gr 0 → PB Gr 334
Gamma-Glutamyl Transferase ↑ BL Gr 1 → PB Gr 362
Gamma-Glutamyl Transferase ↑ BL Gr 1 → PB Gr 403
Amylase ↑ BL Gr 0 → PB Gr 311
Amylase ↑ BL Gr 0 → PB Gr 410
Amylase ↑ BL Gr 1 → PB Gr 301
Lipase ↑ BL Gr 0 → PB Gr 332
Lipase ↑ BL Gr 0 → PB Gr 412
Bilirubin ↑ BL Gr 0 → PB Gr 321
Bilirubin ↑ BL Gr 0 → PB Gr 410
Creatinine ↑ BL Gr NA → PB Gr 302
Hemoglobin ↓ BL Gr 0 → PB Gr 310
Hemoglobin ↓ BL Gr 1 → PB Gr 341
Platelets ↓ BL Gr 0 → PB Gr 376
Platelets ↓ BL Gr 0 → PB Gr 4136
Platelets ↓ BL Gr 1 → PB Gr 312
Platelets ↓ BL Gr 1 → PB Gr 482
Leukocytes ↓ BL Gr 0 → PB Gr 320
Leukocytes ↓ BL Gr 0 → PB Gr 440
Leukocytes ↓ BL Gr 1 → PB Gr 344
Leukocytes ↓ BL Gr 1 → PB Gr 471
Neutrophils ↓ BL Gr 0 → PB Gr 3411
Neutrophils ↓ BL Gr 0 → PB Gr 4233
Lymphocytes ↑ BL Gr 0 → PB Gr 301
Lymphocytes ↓ BL Gr 0 → PB Gr 313
Lymphocytes ↓ BL Gr 0 → PB Gr 411
Lymphocytes ↓ BL Gr 1 → PB Gr 301
Lymphocytes ↓ BL Gr 1 → PB Gr 412
SecondaryKaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

The analysis of 100-day mortality after alloHSCT was assessed for participants who received an alloHSCT while in remission and did not receive any additional anti-leukemic treatment. 100-day mortality after alloHSCT was calculated relative to the date of alloHSCT. The 100-day mortality rate after alloHSCT was defined as the percentage of participants having died up to 100 days after alloHSCT, estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive were censored at the date they were last known to be alive.

Time frame:
From the date of alloHSCT until death/censor date; median follow up time was 1742.0 days for blinatumomab and 1619.0 days for HC3.
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
percentage of participantsHC3 ChemotherapyBlinatumomab
Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)5.1 (1.3 to 19.0)3.9 (1.0 to 14.8)
SecondaryNumber of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)

Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.

Time frame:
Day 1 to Day 29.
Reported as:
Number · participants
Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)
participantsBlinatumomab
Binding Antibody Positive0
Neutralizing Antibody Positive0
SecondaryPharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)
Time frame:
Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
Reported as:
Mean · pg/mL
Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)
pg/mLBlinatumomab
Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)884 ± 969
SecondaryPharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)
Time frame:
Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
Reported as:
Mean · L/hr/m^2
Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)
L/hr/m^2Blinatumomab
Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)1.14 ± 0.836

Adverse events

Collected over All-cause mortality is reported from randomization through the end of study; the median overall follow-up time was 55.2 months. Treatment-emergent adverse events are reported from the first dose of IP through the last dose of IP (up to Day 29) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HC3 Chemotherapy28/57 (49.1%)24/52 (46.2%)48/52 (92.3%)
Blinatumomab11/54 (20.4%)15/54 (27.8%)54/54 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventHC3 ChemotherapyBlinatumomab
Febrile neutropeniaBlood and lymphatic system disorders9/520/54
NeutropeniaBlood and lymphatic system disorders3/520/54
ThrombocytopeniaBlood and lymphatic system disorders2/520/54
StomatitisGastrointestinal disorders2/521/54
Neurological symptomNervous system disorders0/522/54
SeizureNervous system disorders0/522/54
LeukopeniaBlood and lymphatic system disorders1/520/54
Pancreatitis acuteGastrointestinal disorders1/520/54
HepatotoxicityHepatobiliary disorders1/520/54
HypertransaminasaemiaHepatobiliary disorders1/520/54
Most frequent other events
Showing 10 of 54
Most frequent other events
EventHC3 ChemotherapyBlinatumomab
PyrexiaGeneral disorders10/5243/54
StomatitisGastrointestinal disorders27/5211/54
AnaemiaBlood and lymphatic system disorders24/5213/54
NauseaGastrointestinal disorders9/5223/54
HeadacheNervous system disorders8/5220/54
VomitingGastrointestinal disorders11/5217/54
NeutropeniaBlood and lymphatic system disorders13/525/54
DiarrhoeaGastrointestinal disorders9/5212/54
ThrombocytopeniaBlood and lymphatic system disorders11/524/54
Abdominal painGastrointestinal disorders11/527/54

Baseline characteristics

The FAS included all randomized participants analyzed according to their randomized treatment assignment, regardless of the treatment received.

Age, Continuous
Age, Continuous(years)HC3 ChemotherapyBlinatumomabTotal
Mean6.6 ± 4.37.3 ± 4.47.0 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)HC3 ChemotherapyBlinatumomabTotal
Female342458
Male233053
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HC3 ChemotherapyBlinatumomabTotal
Hispanic or Latino314
Not Hispanic or Latino5453107
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HC3 ChemotherapyBlinatumomabTotal
White465096
Other, Not Specified538
Asian314
Black or African American303
Stratification Factor: Age Category
Stratification Factor: Age Category(Participants)HC3 ChemotherapyBlinatumomabTotal
1 to 9 years413980
Other (< 1 year and > 9 years)161531
Stratification Factor: Marrow/Minimal Residual Disease (MRD)
Stratification Factor: Marrow/Minimal Residual Disease (MRD)(participants)HC3 ChemotherapyBlinatumomabTotal
M1 Marrow + MRD level ≥ 10^-3171532
M1 Marrow + MRD level < 10^-3363571
M2 Marrow448
08

Study locations

103 sites
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    Westmead, New South Wales 2145, Australia
  • Research Site
    South Brisbane, Queensland 4101, Australia
  • Research Site
    Parkville, Victoria 3052, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Brussels, 1020, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Curitba, Paraná 81520-060, Brazil
  • Research Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Research Site
    São Paulo, São Paulo 04039-001, Brazil
  • Research Site
    São Paulo, São Paulo 08270-070, Brazil
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13385, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75012, France
  • Research Site
    Paris, 75019, France
  • Research Site
    Strasbourg, 67200, France
  • Research Site
    Vandœuvre-lès-Nancy, 54511, France
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Giessen, 35392, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Jena, 07740, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    München, 80337, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Ulm, 89075, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Goudi, 11527, Greece
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Jerusalem, 9112001, Israel
  • Research Site
    Petah Tikva, 4920235, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Tel Litwinsky, 5262000, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Genova, 16147, Italy
  • Research Site
    Monza (MB), 20900, Italy
  • Research Site
    Naples, 80123, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Guadalajara, Jalisco 44340, Mexico
  • Research Site
    Mexico City, Mexico City 01120, Mexico
  • Research Site
    Monterrey, Nuevo León 64460, Mexico
  • Research Site
    Rotterdam, 3015 CN, Netherlands
  • Research Site
    Utrecht, 3584 CS, Netherlands
  • Research Site
    Oslo, 0372, Norway
  • Research Site
    Bydgoszcz, 85-094, Poland
  • Research Site
    Krakow, 30-663, Poland
  • Research Site
    Lublin, 20-093, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Zabrze, 41-800, Poland
  • Research Site
    Lisbon, 1099-023, Portugal
  • Research Site
    Porto, 4200-072, Portugal
  • Research Site
    Bucharest, 022328, Romania
  • Research Site
    Cluj-Napoca, 400177, Romania
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Málaga, Andalusia 29011, Spain
  • Research Site
    Seville, Andalusia 41013, Spain
  • Research Site
    Santander, Cantabria 39008, Spain
  • Research Site
    Barcelona, Catalonia 08035, Spain
  • Research Site
    Barcelona, Catalonia 08041, Spain
  • Research Site
    Santiago de Compostela, Galicia 15706, Spain
  • Research Site
    Boadilla del Monte, Madrid 28660, Spain
  • Research Site
    El Palmar, Murcia 30120, Spain
  • Research Site
    Valencia, Valencia 46026, Spain
  • Research Site
    Madrid, 28009, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Stockholm, 171 76, Sweden
  • Research Site
    Basel, 4056, Switzerland
  • Research Site
    Zurich, 8032, Switzerland
  • Research Site
    Adana, 01130, Turkey (Türkiye)
  • Research Site
    Antalya, 07059, Turkey (Türkiye)
  • Research Site
    Izmir, 35040, Turkey (Türkiye)
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
  • Research Site
    Birmingham, B4 6NH, United Kingdom
  • Research Site
    Bristol, BS2 8BJ, United Kingdom
  • Research Site
    Glasgow, G51 4TF, United Kingdom
  • Research Site
    London, WC1N 3JH, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom

Showing the first 100 of 103 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, Zeng Y, Pilankar D, Morris J, von Stackelberg A. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Aug;69(8):e29715. doi: 10.1002/pbc.29715. Epub 2022 Apr 28. PubMed 35482538 ↗
  • Blinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade. van Beurden-Tan CHY, Ribeiro RA, Seber A, de Martino Lee ML, Marçola M, Schuetz R, Loggetto SR, Maiolino A. Jornal Brasileiro de Economia da Saúde 14(1): 41-50. 10.21115/JBES.v14.n1.p41-50
  • Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987. PubMed 33651091 ↗
  • Caillon M, Brethon B, van Beurden-Tan C, Supiot R, Le Mezo A, Chauny JV, Majer I, Petit A. Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France. Pharmacoecon Open. 2023 Jul;7(4):639-653. doi: 10.1007/s41669-023-00411-4. Epub 2023 Apr 18. PubMed 37071263 ↗
  • Peters C, Bruno A, Rizzari C, Brescianini A, Von Stackelberg A, Linderkamp C, Zeng Y, Zugmaier G, Locatelli F. Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen. Haematologica. 2025 Jan 1;110(1):234-238. doi: 10.3324/haematol.2024.285837. No abstract available. PubMed 39234873 ↗
  • Locatelli F, Rizzari C, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, Desai R, Henry M, Zugmaier G, von Stackelberg A. Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study. Leukemia. 2026 Jan;40(1):230-234. doi: 10.1038/s41375-025-02800-6. Epub 2025 Nov 13. No abstract available. PubMed 41233549 ↗
  • Diaz Martinez JP, de Maraumont TA, Camacho LM, Garcia L. Cost-effectiveness of blinatumomab for the treatment of B-precursor acute lymphoblastic leukemia pediatric patients with high-risk first-relapse in Mexico. Leuk Res. 2024 Oct;145:107560. doi: 10.1016/j.leukres.2024.107560. Epub 2024 Aug 22. PubMed 39214018 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jul 2019, 44 months.

Results were first posted in Jul 2020, 11 months after primary completion.

Of 59 phase 3 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 104. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2015
First posted
Mar 20, 2015
StartActual
Nov 10, 2015
Primary completionActual
Jul 17, 2019
CompletionActual
Nov 21, 2022
Results first posted
Jul 13, 2020
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02393859
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Nov 10, 2015
Primary completion
Jul 17, 2019
Completion
Nov 21, 2022
Results posted
Jul 13, 2020
Last update
Jun 26, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion